ISLB 2024

#ISLB24

Meet The ISLB 2024 Speakers

Organized By

Get to Know the Speakers

Meet the speakers for the ISLB 2023. In order to learn more about each individual speaker, please click on the photos below.

Alessandro Russo

Categories: Invited Speakers
Alessandro Russo: Italy
Alessandro Russo, MD, PhD
Medical Oncology Unit, Department of Onco-Hematology, Papardo Hospital, Messina, Italy
Dr. Russo is a board-certified medical oncologist with interest in thoracic malignancies, immunotherapy and liquid biopsies.
Dr. Russo degreed as M.D. at the University of Messina (Italy) and there he completed his residency in Medical Oncology. He had his PhD in 2019 in Medical and Surgical Biotechnologies at the University of Messina, with a research project on the role of liquid biopsies as predictive biomarkers to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC). During his PhD, Dr. Russo joined as Visiting Researcher the Division of Thoracic Medical Oncology and Early Clinical Trials at the University of Maryland Medical Center, Greenebaum Comprehensive Cancer Center (Baltimore, USA).
From February 2020 he joined the Medical Oncology Unit of the Papardo Hospital (Messina, Italy) as medical oncologist, with focus on thoracic malignancies.
He is member of several national and international scientific societies, including the International Association for the Study of Lung Cancer (IASLC), the Italian Association of Thoracic Oncology (AIOT), the Italian Association of Medical Oncology (AIOM) and the European Society for Medical Oncology (ESMO). Dr. Russo took part to the Executive Board of the Sicilian Section of the Italian Association of Medical Oncology (AIOM) for the years 2015-2019.
Dr. Russo is co-author of several publications in peer-reviewed international journals, four book chapters, and he is actively involved in clinical research in advanced NSCLC and liquid biopsy

Alessandro Russo

Click To Read Bio

Alexandra Clipson

Categories: Invited Speakers
Alexandra Clipson: UK

Deputy Lead of Nucleic Acids Biomarker Team

Alexandra Clipson

Click To Read Bio

Ana Vivancos

Categories: Invited Speakers
Ana Vivancos: Spain

PI Cancer Genomics Lab @ VHIO

Ana Vivancos

Click To Read Bio

Arsela Prelaj

Categories: Invited Speakers
Arsela Prelaj: Italy
She currently works as a Medical Oncologist with both a strong interest and commitment to translational research at the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan (since September 2018), in the Thoracic Oncology Unit.
In the last five years she has focused her research on Thoracic Malignancies, especially in NSCLC patients treated with immunotherapy and target therapy, being sub and principal investigator of many clinical studies/trials and closely involved in the coordination of various national and international grant applications on this topic.
Indeed, her research focus is also centered on Bioengineering and Artificial Intelligence (AI), as embodied by her enrolment as a PhD student at the Politecnico di Milano’s Department of Electronics, Informatics and Bioengineering in 2019, an activity she conducts in parallel with her clinical duties and research activities. In the last three years she has focused her research on collected real world and multiomics (circulating immune profiling, radiomics, digital pathology, genomics and RNA sequencing) data from advanced NSCLC patients treated with Immunotherapy with the aim to develop an AI tool able to design better individualized treatments and predict their efficacy. The source of the data is primarily a 3-years long translational study, APOLLO, which focused on the biobank samples’ collection from NSCLC patients.
To answer the major unmet need in NSCLC of the identification of efficient biomarkers for immunotherapy, she first co-led a Horizon 2020 grant application in 2020, which was presented anew in 2021 as a large-scale Horizon Europe application which successfully obtained funding – I3LUNG (https://cordis.europa.eu/project/id/101057695) that regards NSCLC, immunotherapy and the implementation of innovative Artificial Intelligence methodologies for the construction of therapeutic decision-making support tools.
In the last years, to propose concrete solutions to unify and harmonize data and biological sample collection among centers she successfully applied for funding at the “Bando di Ricerca Istituzionale” (BRI – Institutional Research Call, promoted by the Institute’s Scientific Directorate to support innovative translational research projects) in 2021. She is the Principal Investigator and Coordinator of the “APOLLO 11” project, a large Italian network (15 centers, which will be expanded to over 40 institutes in 2022-2023) of advanced lung cancer units, focusing on Translational Research and Real-World data with the principal aim to develop of a national database and biobank.
She also recently participated as PI in a Horizon Project call on: High Value for care and research in Lung Cancer and recently submitted a Grant as CO-PI (PI: Dr. Sangaletti) on Bando di Ricerca Finalizzata 2022 on the development of a Bone Marrow-on Chip (a three-dimensional microfluidic device) for the early detection of Lung and Breast Cancer.
She is a very active member of the ESMO Committee ESMO Real world data and digital health in oncology Working Group (RDH WG) to which she was invited in 2020. Her action point focused on three different objectives in the next year: ESMO paper position on guideline regarding Real World Clinical Trials, education and networking, giving her expertise on Big Data and Artificial Intelligence analysis.
She is part of a research-collaborative group on ESMO-ESTRO collaboration on defining guideline for concomitant radiotherapy Innovative therapies (immunotherapy and target therapies across cancers).
Finally, the results of a recent ESMO collaboration will be published, where she will be the first co-author, on ESMO’s position on the use”

Arsela Prelaj

Click To Read Bio

Atocha Romero

Categories: Local Organizing Committee
Atocha Romero: Spain

Atocha Romero is a Laboratory Medicine specialist who holds a Ph.D. in Molecular Biology from Universidad Complutense de Madrid. Presently, Dr. Romero serves as the director of the Liquid Biopsy Laboratory (LBL), from the medical Oncology Department, at Puerta de Hierro Hospital, in Madrid. The LBL provides diagnostic services and undertakes research in the field of cancer biomarkers. Her research predominantly centers on the applicability of liquid biopsies in lung cancer patients in routine oncology as well as in the context of clinical trials. Her research has consistently secured funding through competitive public grant calls. With over 90 publications in international journals to her name, she has also overseen multiple theses and holds accreditation from ANECA as an assistant professor.

Atocha Romero

Click To Read Bio

Beatriz Bellosillo

Categories: Invited Speakers
Beatriz Bellosillo: Spain

Beatriz Bellosillo is the Head of the Molecular Biology laboratory at the Pathology Department of Hospital del Mar, in Barcelona, Spain, and is associate professor at the Pompeu Fabra University of Barcelona. She is an experienced molecular biologist with expertise in translational research in Hematology and Oncology areas in Hospital del Mar Medical Research Institute (IMIM).

She studied Pharmacy from 1988-1993 and developed her PhD studies from1993- 1999 in University of Barcelona. Since her incorporation in Hospital del Mar (Barcelona) in 2001, she has developed the molecular diagnostic area in the Pathology Department with a special focus in the haematological and oncological areas and obtained ISO9001 certification in 2015 and ISO15189 accreditation in 2017. In addition, Dr. Bellosillo participates as assessor in quality programmes of the European Molecular Quality Network, and the Spanish Society of Pathology in the molecular quality programmes.

From the research point of view, Dr. Bellosillo is member of the research programme in cancer in the Hospital del Mar Research Institute and president of the Research Comission, which guarantees the implementation of the scientific policies in the institution.
In accordance with the routine clinical work, her scientific interest has focused in the last years in the assessment of molecular alterations and other biomarkers involved in haematological malignancies and solid tumors, with an especial emphasis in the implementation of liquid biopsy for studying solid tumors

Beatriz Bellosillo

Click To Read Bio

Bernardino Alcazar Navarrete

Categories: Invited Speakers
Bernardino Alcazar Navarrete: Spain
Head of section. Associate profesor

Bernardino Alcazar Navarrete

Click To Read Bio

Charu Aggarwal

Categories: Invited Speakers
Charu Aggarwal: USA
Dr. Aggarwal is the Leslye Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine. Dr. Aggarwal specializes in the management of patients with lung cancer, with a specific and clinical research focus on the development of personalized therapeutic approaches, and the discovery and application of biomarkers to guide treatment. She is a world-renowned expert in the application of plasma-based gene sequencing in the management of patients with metastatic lung cancer, and is actively working on implementation of comprehensive testing, and discovery of approaches focusing on early detection, detection of resistance mutations and disease monitoring.
Dr. Aggarwal serves as the Associate Director of Penn Center for Precision Medicine, and Director of Precision Medicine Innovation at the Penn Center for Cancer Care Innovation (PC3I). In her roles, she is actively involved in developing, implementing, and advancing strategic and operational precision medicine initiatives with a focus on those that involve bringing new technologies or approaches to clinical care and ultimately deliver on the promise of personalized cancer therapy.
She is an active member of the Abramson Cancer Center where she serves as Physician Leader for the clinical research program for Airways Malignancies. Dr. Aggarwal performs patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with Lung Cancer.

Charu Aggarwal

Click To Read Bio

Christian Rolfo

Categories: ISLB Executive Committee
Christian Rolfo: USA
Christian Rolfo, MD, PhD, MBA, Dr.hc. is Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at The Tisch Cancer Institute. Dr. Rolfo’s clinical and research focus is on drug development, lung cancer and other thoracic malignancies, biomarkers, resistant mechanisms discovery, and liquid biopsies. Dr. Rolfo has held academic appointments at numerous institutions, including the University of Cordoba, Argentina; University of Antwerp, Belgium; University of Palermo, Italy, and the University of Maryland and Greenbaum Comprehensive Cancer Center where he was Director of Thoracic Medical Oncology and Director of Early Clinical Trials. Dr. Rolfo earned his MD at the University of Cordoba School of Medicine, his PhD and Doctor Europaeus in Clinical and Experimental Oncology Research at University of Palermo, Italy, and an MBA in Hospital and Health Services Management and Organization at Polytechnic University of Valencia, Spain. He completed residency training in Medical Oncology at the National Cancer Institute in Milan (University of Milan, Italy).
Dr. Rolfo is President of the International Society of Liquid Biopsy (ISLB) and Chair of the Education Committee at the International Association for Study of Lung Cancer (IASLC). Dr. Rolfo served as member of the Drug Approval & First in Human Commission at the Ministry of Health in Belgium during his time as Phase I Director at Antwerp University.
Dr. Rolfo is actively working on drug development and lung cancer and mesothelioma treatment. His research is focused in molecular oncology, targeted therapies and Immunotherapy in thoracic oncology using new techniques in liquid biopsies, specifically in extracellular vesicles and circulating free tumor DNA. His research group identified ALK translocation in exosomes in NSCLC patients, and showed, for the first time, the videos of labeled EVs uptake by living lung cancer cells. He is currently working on the identification of new biomarkers involved in immunotherapy and TKI drug-resistance and early detection of lung cancer with liquid biopsy. Dr. Rolfo has contributed to the development of several compounds including Erlotinib, and the pharmacokinetics of Olaparib, Entrectinib, Selpercatinib, Trastuzumab Duocarmazine, among others.
Dr. Rolfo has authored more than 250 scientific articles, has made several contributions to book chapters, and has served as a book editor. He has published extensively in peer-reviewed journals including New England Journal of Medicine, Lancet Oncology, Cancer Discovery, Nature Clinical Reviews in Oncology, Journal of Thoracic Oncology, Nature Nanotechnology, Clinical Cancer Research, Annals of Oncology, and Lung Cancer among others. Dr. Rolfo is Editor in Chief of Critical Review in Oncology Hematology and Associate Editor at ESMO Open.

Christian Rolfo

Click To Read Bio

Christofer Abbosh

Categories: Invited Speakers
Christofer Abbosh: USA
AstraZeneca

Christofer Abbosh

Click To Read Bio

Nicola Fusco

Categories: Invited Speakers
Nicola Fusco: Italy
Director, Division of Pathology, IEO European Institute of Oncology IRCCS, Milan,. Italy

Nicola Fusco

Click To Read Bio

Delvys Rodriguez

Categories: Invited Speakers
Delvys Rodriguez: Spain

Delvys Rodriguez

Click To Read Bio

Denis Horgan

Categories: Invited Speakers
Denis Horgan: Belgium

Prof. Denis Horgan, a former Director of the European Cancer Patient Coalition, who was also a policy advisor in the European Parliament and worked with various international NGOs on health development projects. In addition, he has published over 70 academic articles related to the area of personalised medicine. Today, Denis is the Editor in Chief of the journal entitled Public Health Genomics and he is the Executive Director of the European Alliance of Personalised Medicine (EAPM). The mix of EAPM members provides extensive scientific, clinical, caring and training expertise in personalised medicine and diagnostics, across patient groups, academia, health professionals and industry. Relevant departments of the European Commission have observer status, as does your own organisation, of course.

Denis Horgan

Click To Read Bio

Diego de Miguel Perez

Categories: Invited Speakers
Diego de Miguel Perez: USA

Diego de Miguel Perez is a postdoctoral research fellow in the Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, USA. His research specializes on the discovery of liquid biopsy biomarkers, including extracellular vesicles and circulating tumor cells for early detection and the prediction of response to treatment in patients with non-small cell lung cancer.

Diego de Miguel Perez

Click To Read Bio

Eloisa Jantus Lewintre

Categories: ISLB Executive Committee
Eloisa Jantus Lewintre: Spain
Eloisa Jantus Lewintre is an Associate Professor of Cell Biology at the Department of Biotechnology, Polytechnic University of Valencia, and the head of the Molecular Oncology Laboratory, eOM Research group at General University Hospital of Valencia Research Foundation. She is a member of the Executive Board of the International Society of Liquid Biopsy (ISLB) and the Director of Master of Biomedical Biotechnology at the Polytechnic University of Valencia. Her main research interest is the discovery of new minimally invasive diagnostic, prognostic and predictive molecular biomarkers in cancer. Her research group has expertise in establishing 3D lung cancer patient-derived organoids to explore the tumor microenvironment’s biology and to test innovative therapeutic approaches in lung cancer.
Currently, she leads national and international projects focused on developing new techniques in liquid biopsy and, more specifically, circulating free nucleic acids.
Dr. Jantus has authored more than 150 scientific articles in peer review and high-impact journals in the oncology field.

Eloisa Jantus Lewintre

Click To Read Bio

Enrique Billalabetia

Categories: Invited Speakers
Enrique Billalabetia: Spain

Engonbil

Enrique Billalabetia

Click To Read Bio

Enriqueta Felip

Categories: Invited Speakers
Enriqueta Felip: Spain

Enriqueta Felip

Click To Read Bio

Evi Lianidou

Categories: Invited Speakers
Evi Lianidou: Greece
Dr. Evi Lianidou is Professor of Analytical Chemistry and Clinical Chemistry at the Department of Chemistry, University of Athens, Greece. Dr Lianidou has established a Molecular Diagnostics Laboratory focused on Liquid Biopsy at the Department of Chemistry since 1998 (http://en.actc-lab.chem.uoa.gr/). Her lab is specializing in the Liquid Biopsy Analysis, Analysis of Circulating Tumor Cells (ACTC) and cell-free DNA, and has access to many patient samples through extensive clinical collaborations. Her main research interests are on the development and clinical evaluation of: a) single-plex and multiplex quantitative RT-qPCR assays for the detection and molecular characterization of CTCs, b) multiplex assays for gene expression in CTCs based on the liquid bead array (LUMINEX platform), c) DNA methylation assays in CTCs and ctDNA, d) highly sensitive assays for mutation analysis in CTCs and in ctDNA, and e) evaluation of circulating miRNAs as tumor biomarkers in plasma. Dr. Lianidou has 166 publications (https://www.ncbi.nlm.nih.gov/pubmed/?term=lianidou) and has organized six international meetings on liquid biopsy: a) the 7th International Symposium on Minimal Residual Disease in Athens, (http://ismrc2009.chem.uoa.gr) , b) the 1st “Advances in Circulating Tumor Cells: From Basic Research to Clinical Practice” (www.actc2012.org), c) the 2nd ACTC meeting, (October 8th-11th, 2014), in Crete, Greece (www.actc2014.org), d) the 3rd ACTC meeting, (October 4th-7th, 2017), in Rhodes, Greece (www.actc2017.org), the 4th ACTC meeting in Corfu, Greece (https://actc2019.org), and the 5th ACTC meeting, Kalamata, Greece, (www.actc2021.org). Prof Lianidou is PI in the European TRANSCAN group “PROLIPSY” and took part in the EU IMI Network Project “CANCER-ID” (www.cancer-id.eu). Dr Lianidou is an elected Board member of the European Association of Cancer Research (EACR), a member of the European Liquid Biopsy Society (ELBS), and serves on the Editorial Boards of many international journals. Dr. Lianidou served International Federation of Clinical Chemistry (IFCC) as an elected member and Chair of the Committee for Clinical Molecular Biology Curriculum (2014-2019, (http://www.ifcc.org/ifcc-education-division/emd-committees/c-cmbc/) and since 2020 is an elected member of the IFCC Committee on Task Force on Global Lab Quality (TF-GLQ), (https://www.ifcc.org/executive-board-and-council/eb-task-forces/task-force-on-global-lab-quality/).

Evi Lianidou

Click To Read Bio

Klaus Pantel

Categories: Invited Speakers
Klaus Pantel: Germany
University Medical Center

Klaus Pantel

Click To Read Bio

Norma Pilnik

Categories: Invited Speakers
Norma Pilnik: Argentina

Norma Pilnik

Click To Read Bio

Gilbert Morgan

Categories: Invited Speakers
Gilbert Morgan: Sweden

Gilbert Morgan

Click To Read Bio

J.F. Pouliot

Categories: Invited Speakers
J.F. Pouliot: USA

Dr. Pouliot completed a doctoral degree in Human Physiology at the University of Montreal and a fellowship at McGill University on multidrug resistance in cancer. With broad experience in clinical development, he worked on numerous phase I – III programs leading to innovative drug approvals, including imatinib in chronic myelogenous leukemia, temozolomide in brain tumors, pembrolizumab and cemiplimab in skin and lung cancer. Over the years, he fostered numerous academia-industry collaborations and investigator-driven initiatives across the Americas, Europe, and Asia. At Regeneron Pharmaceuticals, he leads the global medical affairs team in lung cancer and other solid tumors.

J.F. Pouliot

Click To Read Bio

Clara Mayo De las Casas

Categories: Local Organizing Committee
Clara Mayo De las Casas: Spain

Hospital Universitary Dexeus. Pangaea Oncology Laboratory

Clara Mayo De las Casas

Click To Read Bio

Jean Y Pierga

Categories: Invited Speakers
Jean Y Pierga: France

Medical Oncologist

Jean Y Pierga

Click To Read Bio

Joaquin Dopazo

Categories: Invited Speakers
Joaquin Dopazo: Spain

Dr. Joaquin Dopazo is the director of the Platform of Computational Medicine of the Progress and Health Foundation from the Andalusian Health System. He has a degree in Chemistry and a PhD in Biology (University of Valencia, 1989). He has lead bioinformatics and data science departments in different academic institutions (CIPF in Valencia and CNIO in Madrid) and companies (Glaxo Wellcome, Madrid, Spain). Dr. Dopazo’s interests revolve around functional genomics, systems biology as well as development of new algorithms and software for the analysis of high-throughput genomic data and electronical health record data and its application to personalized and precision medicine and drug discovery, making intensive use of mathematical modeling and artificial intelligence. He has published more than 350 papers in international peer-reviewed journals, reaching an h-index of 70. He has promoted genomic initiatives such as the Medical Genome Project, and has participated in numerous national and international initiatives and consortia (e.g. IMPaCT-data, MAQC, ELIXIR, 1+Million genomes etc.)

Joaquin Dopazo

Click To Read Bio

Laura Mezquita

Categories: Invited Speakers
Laura Mezquita: Spain
Laura Mezquita MD, PhD
Medical oncologist, Thoracic Oncology Group, Medical Oncology Department, Hospital Clinic
Researcher, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS
Adjunct Professor of Medicine, University of Barcelona

Laura Mezquita

Click To Read Bio

Laura Muinelo

Categories: Invited Speakers
Laura Muinelo: Spain
Miguel Servet Researcher at the Health Research Institute of Santiago de Compostela (IDIS). Head of the Liquid Biopsy Analysis Unit at IDIS since 2012. This unit is specialized in the study of circulating biomarkers (CTCs, ctDNA, cEVs) as a tool to characterize tumors and carry out a more personalized
oncology in different tumor types. Colaborator and principal investigator of more than 20 national and international projects focused on the characterization of the dissemination process and the identification of new non-ivasive biomarkers. Author of 81 publications (H Index: 23), three patents (EP19382960.3; EP17382860) and director of 6 doctoral thesis.

Laura Muinelo

Click To Read Bio

Lauren Leiman

Categories: Invited Speakers
Lauren Leiman: USA
Lauren C. Leiman is currently the Executive Director of the Blood Profiling Atlas in Cancer (BLOODPAC), a consortium focused on accelerating the development of safe and effective liquid biopsy technologies for cancer patient benefit. Prior to running BLOODPAC, she was the Senior Director of External Partnerships on the White House Cancer Moonshot Taskforce during the Obama Administration.
Previously, Lauren was a Senior Advisor for the Melanoma Research Alliance and Director of Philanthropy at Elysium Management LLC in New York City. From 2008-2010, Lauren worked for the Millennium Promise Alliance, where she led the major gifts fundraising effort and spent significant time in sub-Saharan Africa. Lauren was also the head of marketing and investor relations at Steel Partners, LP, an activist hedge fund investing globally.
Lauren received her undergraduate degree in communications from the University of Pennsylvania’s Annenberg School. She also holds an MBA in International Business from the University of North Carolina’s Kenan-Flagler Business School and an MS in Public Relations and Corporate Communications from NYU.

Lauren Leiman

Click To Read Bio

Lorena Dieguez

Categories: Invited Speakers
Lorena Dieguez: Portugal
Lorena Diéguez is the leader of the Medical Devices research group at INL. Her research is dedicated to Translational Medical Research in close collaboration with hospitals and focuses on the development of solutions based on microfluidics, biosensors and nanotechnology towards early diagnosis and better understanding of diseases.
She is also very interested in translating her technology from the lab to the clinic and is co-founder and CEO of the spin-off company RUBYnanomed in the field of liquid biopsy. In RUBYnanomed, her role is to bring to market a new tool for patient monitoring and therapy selection in metastatic breast cancer.
Between 2020 and 2021, she was part of the coordination team of INL’s Precise Personalised HealthTech cluster. Also, since 2019 and to date, she is the Chair of the Working Group in Medical Devices at the ETPN (European Technology Platform in Nanomedicine).
She obtained her Bachelors in Physics with Major in Optoelectronics at the University of Santiago de Compostela in 2005, then completed her Masters in Nanotechnology at the University of Barcelona (UB) in 2007 and her PhD in biosensors at the UB, the Institute for Bioengineering of Catalonia and the ETH Zürich. Her postdoc at the University of South Australia (2010-2013) was devoted to the study of rare cells from biological samples using microfluidics. Lorena joined INL in 2014 as Staff Researcher, before being promoted to Research Group Leader in 2018.
She has published over 43 peer-reviewed research articles, reviews, and book chapters. She has participated in 26 national and international research projects, 17 of them as PI, and 6 of them as coordinator. She has also authored 5 patents, and been invited, keynote or plenary speaker in over 30 international conferences. She has also been recipient of several international research and innovation awards.

Lorena Dieguez

Click To Read Bio

Luis Paz Ares

Categories: Invited Speakers
Luis Paz Ares: Spain
Dr. Paz-Ares (MD, Ph.D.) is currently Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at National Oncology Research Center, all in Madrid.He graduated with a degree in Medicine from the Universidad Autónoma de Madrid, in 1986, and was trained as a resident in Medical Oncology at Hospital 12 de Octubre (1988-2001). In 1993, he completed a Ph.D. in Medicine at the Universidad Autónoma de Madrid. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, (1993– 1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995.
Before the current position he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), Head of the Pharmacology Unit and responsible for Early Clinical Studies of Thoracic and Genitourinary Tumours at the University Hospital “12 de Octubre” in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).
Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 340 articles in peer review journals including New England Journal of Medicine, Lancet, Lancet Oncology, Nature Medicine, Journal of Clinical Oncology and many others. He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, European Organisation for Research and Treatment of Cancer Protocol Review Committee and Audit Committee, the Spanish Agency of Medicines and Medical Devices and the European Medicines Agency. He is the Chief Medical Officer of the AECC where he also seats at the Board.

Luis Paz Ares

Click To Read Bio

Luis Raez

Categories: Invited Speakers
Luis Raez: USA

Luis E. Raez, MD, FACP, FCCP works as Chief Scientific Officer & Medical Director at Memorial Cancer Institute (MCI)/Memorial Health Care System, he is also Director of the Thoracic Oncology Program. He is Co-Director of the MCI/FAU Florida Cancer Center of Excellence designated by the Florida Department of Health, one of only five cancer centers in Florida. He is also Clinical Professor of Medicine at Florida International University (FIU), Visiting Professor of Medicine at Cayetano Heredia University in Peru and Research Professor at Florida Atlantic University (FAU). He was the President of the Florida Society of Clinical Oncology (FLASCO) 2019-2021.

Luis Raez

Click To Read Bio

Maria Arcila

Categories: Invited Speakers
Maria Arcila: USA

Dr. Arcila is a molecular genetic pathologist and hematopathologist with a specific interest in cancer diagnostics.

Maria Arcila

Click To Read Bio

Maria Jesus Pareja

Categories: Local Organizing Committee
Maria Jesus Pareja: Spain

Medico especialista en Anatomía Patologica. Hospital Universitario Virgen del Rocio. Sevilla

Maria Jesus Pareja

Click To Read Bio

Maria Jose Serrano

Categories: ISLB Executive Committee
Maria Jose Serrano: Spain
Principal Investigator of the Liquid Biopsy and Cancer Interception (LiqBiopCI) group at Virgen de las Nieves University Hospital and the GENyO center in Granada. I am also an associate professor in the Department of Pathological Anatomy at the University of Granada. My career has been dedicated to cancer research, with a primary focus on the field of liquid biopsy. I have undertaken various research visits both within Spain (Basque Country, Catalonia, Madrid) and abroad (Tromso, Norway).
I am the author of over 100 articles, the majority of which center around liquid biopsy research. My work has been published in prestigious journals such as Lancet, Annals of Oncology, and Cancer Discovery. I lead both national and international research projects. Currently, I am overseeing a national project funded by the European Commission and the Ministry of Innovation and Technology of Spain. This project aims to facilitate the clinical implementation of liquid biopsy in Andalusian Hospitals through the Innovative Public Procurement program. Notably, the outcomes of these projects have led to internationally licensed patents.
I am a co-founder and currently hold the position of Vice President at the International Society for Liquid Biopsy (ISLB). Moreover, I serve as the coordinator of PANMEP, the Andalusian Precision Medicine program, which is sponsored by the Ministry of Health of Andalucia. This program is dedicated to training clinical personnel in new diagnostic methodologies. Additionally, since 2022, I have held the role of Innovative Health Andalusia Public Procurement Coordinator.
Furthermore, I am an Associate Editor at CROH and Frontiers in Cell and Developmental Biology, as well as at the Journal of Liquid Biopsy (JLB).

Maria Jose Serrano

Click To Read Bio

Masahiro Tsuboi

Categories: Invited Speakers
Masahiro Tsuboi: Japan
Dr Masahiro Tsuboi is a chair and a director of department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan, and a visiting professor, Department of Surgery, Yokohama City University Graduate school of Medicine, Yokohama, Japan
Dr Tsuboi is a past board director of International Association for the Study of Lung Cancer (IASLC), a past chair of the Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group (JCOG), and a past board director of World Association of Bronchology and Interventional Pulmonology (WABIP).
Dr Tsuboi is involved in numerous perioperative adjuvant and surgical clinical trials. And he has participated as principal investigator or steering committee member in several international studies, such as ADAURA and NeoADAURA, in neoadjuvant/adjuvant setting.
Recently, one of his interests is liquid biopsy for screening and patient selection for perioperative treatment.

Masahiro Tsuboi

Click To Read Bio

Massimo Cristofanilli

Categories: ISLB Executive Committee
Massimo Cristofanilli: USA
Weill Cornell Medicine

Massimo Cristofanilli

Click To Read Bio

Miguel Milan

Categories: Invited Speakers
Miguel Milan: Spain
Dr. Miguel Milan graduated in Biology in 1999 and completed the Ph.D. degree in 2007 at the University of Valencia, Spain, in Cell Biology.
More than 25 years of experience in clinical and research laboratory, beginning in the Department of Cell Biology of the University of Valencia and joining the Preimplantation Genetic Diagnosis Unit at the University Institute-IVI of Valencia in 2006. Since 2015, he is the responsible of the Prenatal Genetic Diagnosis area, including the screening of free circulating DNA in maternal blood for the evaluation of aneuploidies (NACE test, Igenomix).
As an author, he has written numerous book chapters, scientific articles in international journals, and has participated in numerous national and international conferences. He also performs in numerous activities for the training and dissemination of results and special cases.

Miguel Milan

Click To Read Bio

Natasha Leighl

Categories: Invited Speakers
Natasha Leighl: Canada
Dr Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and is Professor in the Department of Medicine, and Adjunct Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto. She holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation. She has published over 350 peer-reviewed grant funding. She has mentored many trainees, that have gone on to leadership roles in oncology around the world, and received the American Society of Clinical Oncology Excellence in Teaching Awards in 2019.

Natasha Leighl

Click To Read Bio

Navneet Singh

Categories: Invited Speakers
Navneet Singh: India
Dr. Navneet Singh MD DM is a thoracic medical oncologist and tenured (full) Professor of Pulmonary Medicine at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Prof. Singh is the coordinator-cum-convener for PGIMER’s multidisciplinary thoracic oncology group that received the Lung Cancer Care Team Award of the International Association for Study of Lung Cancer (IASLC) at its 20th World Conference on Lung Cancer (WCLC) in Barcelona, Spain [2019].
Dr. Singh has been elected fellow of Royal College of Physicians (London), American College of Physicians (FACP), American College of Chest Physicians (FCCP) and Indian Chest Society. He has served as a reviewer for several international journals including New England Journal of Medicine and the Lancet group. He has 200+ publications in peer reviewed medical journals, authored several chapters in books and is an invited faculty and program committee member for IASLC’s annual WCLC. He is /has been member of IASLC’s Staging and Prognostic Factors Committee; Education-; Membership- and Publications- Committees as well.
A past recipient of the International Development & Education Award (IDEA) of American Society of Clinical Oncology (ASCO), Prof. Singh served as Chair of ASCO’s IDEA steering group (2018-20) and is currently Co-Chair of ASCO’s expert panel responsible for ‘living’ guideline on systemic therapy for stage IV NSCLC. Previously, he has been an invited member of ASCO’s special awards selection committee and thoracic cancer guideline group including expert panels that developed clinical practice guidelines on A) Molecular Biomarker Testing in advanced/metastatic NSCLC; B) Surveillance after curative-intent treatment of lung cancer; C) Systemic therapy for stage-IV NSCLC; D) Management of stage III NSCLC (co-chair) all being published in ASCO’s flagship Journal of Clinical Oncology.
Dr. Singh has been a recipient of several awards and honors for his contribution in the area of lung cancer including American Association of Cancer Research-National Cancer Institute (AACR-NCI) International Investigator Opportunity Grant (2009); European Society for Medical Oncology’s (ESMO)’s Translational Research Unit Visit (2010) and Palliative Care (2012-13) Fellowships; Kamal Satbir Award of the Indian Council for Medical Research (ICMR; 2014) and ISSLC’s Oration on Lung Cancer (2017) in addition to travel grants for several international meetings. Very recently, he has been chosen to be conferred with the Fellowship of ASCO (FASCO).

Navneet Singh

Click To Read Bio

David Gandara

Categories: ISLB Executive Committee
David Gandara: USA
David Gandara, Professor of Medicine Emeritus at the University of California, Davis. He is the co-director of the Center for Experimental Therapeutics in Cancer and Senior Advisor to the Director at UC Davis Comprehensive Cancer Center. He was recently appointed Adjunct Clinical Professor, Translational and Clinical Research Program at the University of Hawaii Cancer Center and Chief Medical Officer for International Society of Liquid Biopsy (ISLB) a non-profit organization dedicated to advancing the science and clinical application of liquid biopsy in cancer diagnosis and therapy. He is an internationally known clinician-scientist and lung cancer thought leader, and has published over 450 peer-reviewed papers. He has led many notable research projects in lung cancer including early therapeutics trials through an N01-sponsored award, cooperative group trials as past-chair of the SWOG Lung Committee, and multi-institutional translational science projects such as clinical director of the patient-derived xenograft (PDX) lung program in collaboration with The Jackson Laboratory Cancer Center. Dr. Gandara has been selected for many awards and honors including the lifetime Scientific Award from the International Association for Study of Lung Cancer (IASLC), the Team Science Award from the Addario Lung Cancer Foundation, and the Trajectory Achievement Award from the ISLB. He is current principal investigator for a National Cancer Institute UG1 award to UCDCCC for cancer clinical trials, co-leader of Lung MAP, a unique NCI-sponsored public-private partnership for new drug development in lung cancer, and is founding co-chair and current member of the NCI-directed Investigational Drug Steering Committee (IDSC). Dr. Gandara is past Editor-in-Chief of the journal Clinical Lung Cancer. He served as president of the IASLC from 2009-2011 and as treasurer from 2013-2017. He is a prior member of the board of directors and secretary-treasurer of ASCO. In 2017, Gandara received the Giants of Cancer Care Award in lung cancer.

David Gandara

Click To Read Bio

Nir Peled

Categories: Invited Speakers
Nir Peled: Israel

Nir Peled

Click To Read Bio

Noelia Tarazona

Categories: Invited Speakers
Noelia Tarazona: Spain
In 2007, I earned my MD degree from the University of Valencia. Following that, I completed my medical training in Oncology at the Hospital Clinico Universitario in Valencia, Spain, under the mentorship of Professor Andrés Cervantes. In 2012, I pursued postgraduate studies in Molecular Oncology, with a particular focus on translational research in Gastrointestinal Cancer. To further enhance my knowledge in this field, I undertook a Master’s Degree in Immuno-Oncology at the University of Navarra in 2019.
In 2013, I was awarded the ESMO Translational Research Fellowship and subsequently joined the Gastrointestinal Unit at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London. During my two-year fellowship, under the guidance of Professors David Cunningham and Nicholas Turner, I was actively engaged in various clinical research projects in early drug development and gastrointestinal cancer. My work was specifically centered on understanding the FGFR signaling pathway as a potential therapeutic target for breast and gastric cancer.
Starting in 2015, I progressively shifted my focus toward liquid biopsy and its role in providing valuable insights into minimal residual disease, tumor genotyping, molecular mechanisms of treatment resistance, and potential therapeutic targets across different cancer types. I obtained my PhD in July 2019. Presently, I am actively involved in setting up the CIBERONC Liquid Biopsy Working Module in Spain.
In 2017, I achieved the Certificate of Excellence from the European Society for Medical Oncology (ESMO) after successfully passing an exam in Madrid. This recognition led to my selection to participate in the 2018 ESMO Leaders Generation Programme. Currently, I am an active member of the ESMO Translational Research and Precision Medicine Working Group. I serve as the principal investigator for several translational projects funded by Mutua Madrileña, SEOM, ISCIII, and TTD. Additionally, I hold a position on the Executive Committee of the Spanish Society of Medical Oncology (SEOM) + MIR.

Noelia Tarazona

Click To Read Bio

Ola Khorshid

Categories: Invited Speakers
Ola Khorshid: Egypt
Dr. Ola M. Reda Khorshid
MD. PhD Prof of Medical Oncology NCI Cairo University
Dr Ola Khorshid is currently the department Chair of the Medical Oncology Department NCI Cairo University.
Prof. of Medical Oncology, Malignant Hematology & BMT, Medical Oncology Department NCI, Cairo University
She is the Chairman & Founder of Millennium HealthCare institution Chairman of Onco thoracic International Clinical Association OnTiC Cofounder of Orchid Oncology Center
Secretary General of the Mediterranean Multidisciplinary Oncology Forum (MMOF) She received her master (1998) and PhD (2004) degrees in medical oncology and hematological malignancies from the NCI Cairo University. She has been ESMO certified since 2006
She has trained in MD Anderson Cancer center 2002 and was a Post Doctoral Fellow in MDAnderson Cancer center, Blood and Marrow transplant department,
Developer of Medical oncology curriculum for Medical Oncology Fellowship for the Egyptian Fellowship Board 2008
She is an examiner in the Master & PhD degree of Medical Oncology Cairo University.
She is also an examiner for the Kenyan oncology board.
She was Secretary General of the Egyptian Hemato Oncology Group (EHOG) 2008-2011
She was the clinical instructor and Medical oncologist at Dar Al Fouad Hospital during the period from August 2004 to June 2005: was the person in charge of
developing the SOP and all requirements for the Joint Committee of International Accreditation
She is the winner of the Cairo University Achievement Award for 2011
Dr Khorshid is currently an assistant editor of MEDITERRANEAN ONCOLOGY JOURNAL –M.O.J
She has numerous international publications in SCT, hematological malignancies and solid tumor.
Her main research interest is in Lung, GU, Breast Cancer, GIT malignancies,Lymphoma, Leukemia & BMT

Ola Khorshid

Click To Read Bio

Paraskevi Giannakakou

Categories: Invited Speakers
Paraskevi Giannakakou: USA

Professor of Pharmacology in Medicine, Weill Cornell Medicine

Paraskevi Giannakakou

Click To Read Bio

Pascale Morel

Categories: Invited Speakers
Pascale Morel: France

Dr Pascale Morel has been working in the pharmaceutical industry in various international roles, such as Marketing, Clinical Development and Medical Affairs. Pascale has also worked in the clinical diagnostics and Life Sciences sector at companies like Nanostring or Guardant Heath. Her career has a strong focus on oncology and haemato-oncology, in scope of drug clinical development, clinical genomics and molecular biology, including contributing to the effort of introducing liquid biopsies testing from the industry perspective. Pascale now serves as Senior Medical Affairs Director for the Translational Sciences and Precision Diagnostics franchise at Qiagen, where her mission fits her professional priority which is to contribute in implementing clinical diagnostics tools to make personalized medicine more and more a reality for patients.

Pascale Morel

Click To Read Bio

Pashtoon Kasi

Categories: Invited Speakers
Pashtoon Kasi: USA

I am oncologist and researcher focused on treating patients with gastrointestinal cancers and other solid tumors using novel clinical trials and therapies. My focus has been on understanding the genomics and genetics of the underlying cancer and the person affected by it in order to help treat these cancers in a more personalized fashion. This is often referred to as precision medicine or precision oncology. My research and incorporation of other non-invasive tests like circulating tumor DNA (ctDNA) testing (often referred to as “liquid biopsies”) allows me to not only understand the genetic makeup of every patient that we see, but also to study the changes over time to identify the best treatments for my patients, including clinical trials with novel drugs as single agents or combinations (targeted therapies, immunotherapy, biologics, vaccines, etc.) besides or in addition to the traditional chemotherapy. It is an exciting time to be an oncologist and scientist in the field of oncology and cancer care.

Pashtoon Kasi

Click To Read Bio

Paul Hofman

Categories: Invited Speakers
Paul Hofman: France

Paul Hofman, MD, PhD, is Professor of Pathology at the University Côte D’Azur (Nice, France). He is the Head of the Laboratory of Clinical and Experimental Pathology at Louis Pasteur Hospital and Director of the Research team 4 at the Inserm U1081/CNRS 7284 center (Comprehensive Cancer Center Antoine Lacassagne, Fr). He is the Director of the MSc Biobanks and Complex Data Management. He is the Head of the OncoAge consortium (www.oncoage.org) at the University Côte d’Azur. His main field of interest during these last few years focused on lung cancer pathophysiology, including the assessment of different predictive biomarkers using tissue and liquid biopsies. He is a member of the Royal Academia of Medicine in Brussels.

Paul Hofman

Click To Read Bio

Paz Vellanki

Categories: Invited Speakers
Paz Vellanki: USA

Food and Drug Administration (FDA)

Paz Vellanki

Click To Read Bio

Rafael Lopez

Categories: Invited Speakers
Rafael Lopez: Spain
University Clinical Hospital

Rafael Lopez

Click To Read Bio

Rafael Rosell

Categories: 2023 Awardee
Rafael Rosell: Spain
Dr. Rafael Rosell is Head of the Molecular and Cellular Oncology Laboratory program at the Germans Trias i Pujol Research Institute and Hospital (IGTP), Campus Can Ruti, (Badalona, Barcelona, Spain), past Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona), Chief Scientific Officer, Chairman and Founder of Pangaea Oncology SL (Barcelona), Chief Medical Officer and President of the Dr Rosell Oncology Institute (IOR), Quirón Dexeus, General de Catalunya & Sagrat Cor Univ. Hospitals (Barcelona), and Founder and President of the Molecular Oncology Research Foundation (Barcelona). He is Founder and Director of International Relations and Projects, Spanish Lung Cancer Group (SLCG), member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP) and on the Foundation Board of the ETOP- International Breast Cancer Study Group (IBCSG). He is also a Panel member of the ASCO Clinical Practice Living Guidelines- Systemic Therapy for Stage IV NSCLC.
Dr. Rosell’s contributions to translational medical oncology, with particular emphasis in the field of non-small-cell lung cancer with EGFR mutations, have earned him international renown.
His five greatest contributions to research are as follows:
1. Rosell’s first prima facie study, improving survival based on neoadjuvant chemotherapy in resectable non-small cell lung cancer patients (Stage IIIAN2), transformed the management of NSCLC worldwide (Rosell et al. N Engl J Med. 1994).
2. In 2004, Rosell conducted the first large-scale screening study on EGFR mutations in NSCLC, showing survival benefit in 217 patients treated with erlotinib (Rosell et al. NEJM 2009).
3. Rosell’s EURTAC study (Rosell et al. Lancet Oncology 2012) led to FDA approval of erlotinib as first-line treatment in EGFR-mutant NSCLC.
4. In 2013, Rosell was recognized by The Lancet as the highest authority in lung cancer. (David Holmes: Rafael Rosell: leading the long march against lung cancer: Lancet, 2013)
5. Rosell pioneered the study of evading resistance mechanisms to targeted therapy by bypassing signaling pathways, STAT3 and YAP, and collaborated with other international groups on the subject (Rosell, Bivona, Karachaliou, Lancet 382:720-730, 2013).
Dr. Rosell is fully dedicated to the improvement of lung cancer therapy. His current research programs include continued investigation in translational/preclinical research, liquid biopsy, and novel technologies with NGS. In 2018, he was selected to participate in The European Liquid Biopsy Academy (ELBA).
Dr. Rosell has authored over 700 articles in scientific journals. From 2012 to 2021, he has written more than fifteen invited comments in The British Journal of Cancer, The Lancet, Lancet Oncology, Lancet Respiratory Medicine, among others, including:
1. Arrieta et al. Efficacy and safety of pembrolizumab plus docetaxel alone in patients w/ previously treated advanced NSCLC. The PROLUNG phase 2 randomized clinical trial. JAMA Oncol 2020.
2. Gonzalez-Cao et al. Assessment of feasibility and safety of durvalumab for treatment of solid tumors in patients w/HIV-1 infection. Phase 2 DURVAST study. JAMA Oncol 2020.
3. Arrieta et al. Effect of metformin plus TKIs compared with TKIs alone in patients w/EGFR -mutated lung adenocarcinoma. Phase 2 randomized clinical trial. JAMA Oncol 2019.
4. Rosell et al. Erlotinib and bevacizumab in patients w/advanced NSCLC and activating mutations (BELIEF). Intl, multicenter, single-arm, phase 2 trial. Lancet Resp Med 2017.
5. Chaib et al. Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC. JNCI 2017.
Prominent awards:
• Mary J Mathews Distinguished Service award, IASCL, WCLC 2022
• Bonnie J. Addario Lectureship Award recipient at the International Lung Cancer Congress® (ILCC), 2022
• Raymond Bourgine, ICACT, 2012
• Hamilton Fairley Award, ESMO, 2011
• Eminent Clinical Scholar in Residence, Emory University, Atlanta, 2005

Rafael Rosell

Click To Read Bio

Simon Heeke

Categories: Invited Speakers
Simon Heeke: USA
Simon Heeke received his Bachelor’s and Master’s degree in molecular medicine from the Medical University in Innsbruck, Austria, followed by a PhD in cell biology from the University Côte d’Azur in Nice, under the supervision of Pr. Paul Hofman. After his postdoctoral fellowship in the laboratory of John V. Heymach in the Department of Thoracic Head & Neck Medical Oncology at the MD Anderson Cancer Center in Houston, Texas, he joined faculty as assistant professor in the same department in 2023. Dr. Heeke’s research focuses on the development of innovative biomarkers in lung cancer, particularly in small-cell lung cancer and oncogene-driven non-small cell lung cancer. Dr. Heeke has a strong interest in liquid biopsy-based approaches and serves as the current chair of the young committee at the International Society for Liquid Biopsy.

Simon Heeke

Click To Read Bio

Simon Patton

Categories: Invited Speakers
Simon Patton: UK
Simon Patton, PhD is Chief Executive of EMQN CIC – a global leader in the provision of genomics focussed External Quality Assessment (EQA) / Proficiency Testing (PT) schemes. He trained at the University of Liverpool in marine biology, before doing his doctorate in Genetics at the University of Cambridge. Simon’s career has focussed on driving improvements in the standardisation and quality of diagnostic laboratory testing – a field that he has worked in since 1999 through his involvement with the EMQN.  Simon has extensive knowledge of the clinical healthcare molecular diagnostics field, focussing on genomics (genetics, pathology, technology). He is passionate about ensuring equity of access to accurate high-quality genomic testing for all patients.  Simon has worked in the UK public sector (NHS; Manchester University NHS Foundation Trust (MFT) for most of his career. He joined the NHS in 1999 as the Executive Administrator for EMQN which was at that time funded by a European Commission grant. Over the following years, Simon has been instrumental in helping the business to grow, expanding its membership to more that 2500 laboratories in 85 different countries, and overseeing its successful spin out from the UK NHS in 2021 into an independent private company.

Simon Patton

Click To Read Bio

Solange Peters

Categories: Invited Speakers
Solange Peters: Switzerland

Solange Peters

Click To Read Bio

Sylvan Baca

Categories: Invited Speakers
Sylvan Baca: USA

Sylvan Baca is an Assistant Professor of Medicine at Harvard Medical School, a medical oncologist at the Dana-Farber Cancer Institute, and an Associate Member of the Broad Institute. Raised in Albuquerque, NM, Dr. Baca received his undergraduate degree from Stanford University and his MD and PhD from Harvard Medical School. He trained in Internal Medicine at Brigham and Women’s Hospital and completed his fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Baca received his post-doctoral training in cancer epigenetics with Dr. Matthew Freedman at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. He is on faculty at the Dana-Farber Cancer Institute as a Physician and Investigator. In addition to caring for patients, he conducts research at the interface of computational biology and epigenomics to find better ways to treat cancer.

Sylvan Baca

Click To Read Bio

Umberto Malapelle

Categories: ISLB Executive Committee
Umberto Malapelle: Italy
Currently is the Chair of Predictive Molecular Pathology Laboratory, Department of Public Health of University Federico II of Naples.
His main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumor. Moreover, he has developed skills in tailoring Next Generation Assays for several different applications with a special focus on the simultaneously detection of clinically relevant alterations (i.e., EGFR mutations, ALK translocation, PD–L1 expression) in the routine setting including handling of different sample types, such as tissues and/or liquid biopsy specimens. He serves as Scientific Secretary of International Society of Liquid Biopsy (ISLB) and Editor in Chief of The Journal of Liquid Biopsy, the official Journal of ISLB.

Umberto Malapelle

Click To Read Bio

Valeria Cecilia Denninghoff

Categories: Invited Speakers
Valeria Cecilia Denninghoff: Spain
UBA-CONiCET, Argentina
GENyO, FPS, Spain

Valeria Cecilia Denninghoff

Click To Read Bio

Valsamo Anagnostou

Categories: 2023 Awardee
Valsamo Anagnostou: USA

Dr. Anagnostou is an Associate Professor of Oncology, Director of the Thoracic Oncology Biorepository, co-leader of the Molecular Tumor Board and co-director of the Lung Cancer Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She graduated from Medical School of the National and Kapodistrian University of Athens, Greece and
received a PhD from the same institution. Dr. Anagnostou completed her internal medicine residency at Yale-New Haven Hospital and subsequently trained in Medical Oncology at Johns Hopkins. She is a translational cancer investigator who is focusing on large-scale genomic, multi-omic and liquid biopsy analyses in human cancers. Her research is particularly focused on understanding the molecular mechanisms of response and resistance to immunotherapy and translating this knowledge into minimally invasive approaches for cancer detection, monitoring and interception for patients treated with immunotherapy. Her
long term goal is to transform medical oncology to molecular oncology, where treatment decisions are tailored not only to a baseline genotype but are also informed by real-time dynamics of liquid biopsies.

Valsamo Anagnostou

Click To Read Bio

Yüksel Ürün

Categories: Invited Speakers
Yüksel Ürün: Turkey
Dr. Ürün is a professor of medicine at the Ankara University School of Medicine in Turkey, specializing in Medical Oncology. Since joining Ankara University School of Medicine in 2009, he has played a pivotal role in advancing medical knowledge and expertise in his field. To further enrich his understanding of oncology, Dr. Ürün pursued a fellowship at the renowned Dana Farber Cancer Institute, affiliated with Harvard Medical School in Boston, USA. During this time, he gained invaluable experience and exposure to cutting-edge research and treatments, augmenting his expertise in cancer care.
Upon returning to Turkey, Dr. Ürün’s passion for enhancing cancer treatment and research led him to establish the Turkish Oncology Group Kidney Cancer Consortium (TKCC). Actively engaged in the global oncology community, Dr. Ürün is a prominent member of prestigious international and national oncology organizations. Notably, he is a member of the EORTC GU group and the Advanced Prostate Cancer Consensus Conference (APCCC). Additionally, he serves as a faculty member in the ESMO Genitourinary Tumors, Prostate group. Dr. Ürün has been selected as a participant in the prestigious American Society of Clinical Oncology’s (ASCO) Leadership Development Program class of 2023-2024.
Dr. Ürün’s primary research interests encompass various aspects of genitourinary cancers, including epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. As a principal investigator in numerous clinical trials, he has made remarkable contributions to the scientific community, authoring over 100 peer-reviewed articles, presentations, and book chapters.
Beyond his academic pursuits, Dr. Ürün is deeply committed to promoting diversity and equity in education and healthcare. He is passionate about fostering representation and engagement of underrepresented groups in clinical trials, recognizing the importance of inclusivity and accessibility in the pursuit of medical advancements. Through his passion for patient care and research, he continues to inspire and drive positive change within the field of medicine.

Yüksel Ürün

Click To Read Bio